Cipla Q3 Results: Net profit jumps 49% to ₹1,570 crore; shares up 5%

The pharma major had posted a consolidated net profit of ₹1,056 crore during the same period last fiscal year.

Its consolidated total revenue from operations during the reporting quarter grew 7.1% to ₹7,072.97 crore as against ₹6,603.81 crore in the year-ago period.

“I am pleased to share that we continue to make considerable progress across our focused markets. In Q3FY25, we delivered growth across all our various geographies, despite a supply challenge in the US,” said Umang Vohra, managing director and global CEO of Cipla, in a statement.

Post the earnings, shares of the company zoomed over 5% on both indices. During the intraday trade on BSE, the pharma company was trading at ₹1,471.85 a piece, advancing 5.44%.

The company has also seen the highest-ever EBITDA margin of 28.1%, driven by mix and other operational efficiencies, it said in a regulatory filing.

"With positive traction in our differentiated assets, the US business posted a revenue of $226 million. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in the future pipeline, as well as focusing on resolutions on the regulatory front," Vohra further said.

Cipla’s One India business grew at a healthy 10% year-on-year (y-o-y). The branded prescription business continued to outpace the market growth in key therapies. In South Africa, the company recorded a growth of 21% y-o-y in local currency terms. Emerging Markets and Europe also delivered substantial revenue growth of 20% y-o-y on the back of a deep market focus strategy.

Research and development (R&D) investments of Cipla stood at ₹360 crore, or 5.1% of sales, during the reporting quarter, driven by product filings and development efforts.

[Also read: Why is the healthcare sector outperforming even as the NIFTY50 struggles?

Early in January 2025, Cipla launched a mobile application designed to enable the first line of screening for asthma in India.

"By leveraging the power of next-gen technologies, we are developing solutions that are fundamentally transforming patient care and enabling better diagnostic, treatment, and management outcomes," Vohra had said in a statement.